Trial Profile
A Phase II Study of BAY 43-9006 [sorafenib] in Combination With Bicalutamide in Patients With Chemo-Naive Hormone Refractory Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 04 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 04 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Oct 2009 Actual initiation date (Mar 2007) and actual patient number (39) added as reported by ClinicalTrials.gov.